Patients' characteristics
MIBC, malignancy, tumor, Bacillus
TUMOR, MAY, INFECTION, LIVER METASTASIS, METASTASES
Forty‐three patients with MIBC were enrolled from May 2020 to July 2021 at nine centers in China, and all received the study drugs. Three of the enrolled patients were found ineligible during the study (one with liver metastasis, one with an active infection, and one with another malignancy) and were excluded from the baseline and efficacy analysis (Figure Flowchart of patients.Baseline characteristics of eligible patients (
Abbreviations: BCG, Bacillus Calmette‐Guerin; ECOG PS, eastern cooperative oncology group performance status; TNM, tumor, nodes, metastases.